Skip to main content

Table 4 (A) Analysis of median of overall survival received interventions (BCc1nanomedicine or placebo) and chemotherapy simultaneously. (B) Death rate analysis received interventions (BCc1nanomedicine or placebo) and chemotherapy simultaneously

From: A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

Group

Metastatic

Non- metastatic

Total number

BCc1(n = 14)

Placebo (n = 19)

BCc1(n = 12)

Placebo (n = 20)

(A) Median of overall survival analysis

Median (days)

302

107

482

265

Std. error

133.23

55.09

–a

27.769

Median 95% CI (lower)

40.87

0

–a

210.573

Median 95% CI (upper)

563.13

214.98

–a

319.427

P-value for test of equality of survival distributions

0.306

0.019

HRb

(BCc1/Placebo)

0.589

0.019

Stage (n)

 I

0

0

0

0

 II

0

0

0

3

 III

0

0

11

10

 IIII

14

19

0

0

(B) Death rate analysis

Death rate (%)

50

53

0

35

  1. Test of equality of survival distributions (for Bcc1 and placebo groups) assay with Log Rank (Mantel-Cox)
  2. aNo statistics are computed because all cases are censored
  3. bUnivariate cox regression model